Checkpoints When Choosing "Domestically Produced CBD E-Liquid" | Domestic Manufacturing Labels, THC Residual Limits & How to Read a COA

Corrected on 2026-10-20:retracted the purchase recommendations for specific low-priced domestically produced CBD e-liquids found in the old draft, and organized the legal regulations and quality verification criteria when checking CBD products labeled as "domestically produced / made in Japan."

Do Not Skip Checking the Certificate of Analysis (COA) Just Because of a "Made in Japan" Label

In CBD e-liquids, labels such as "domestically produced" or "manufactured in Japan" usually mean that CBD raw materials (such as isolate powder) imported from overseas were mixed and filled with PG, VG, and flavorings at a factory in Japan.

Even if a product is blended in Japan,compliance with the Δ9-THC residual limits enforced on 2024-12-12 (1ppm for the "Other" category including e-liquids, and 10ppm for oils, fats, and powders) or the CBN designated substance regulation enforced on 2026-6-1 is not automatically guaranteed.In fact, on 2026-4-8, Δ9-THC exceeding the legal limit was detected in a specific CBD wax product distributed in Japan, prompting the Ministry of Health, Labour and Welfare to issue a public warning (Source:Ministry of Health, Labour and Welfare: Warning on the Affected Product）。

CBD, THC, and CBN Are Different Substances: Check the 2026 Regulations

CBD (cannabidiol), CBN (cannabinol), and Δ9-THC are distinct compounds treated differently under Japanese law. Product names or package labels such as "CBD Product" or "Hemp-Derived" alone cannot determine all contained ingredients or legal compliance.

CBN became a designated substance on 2026-6-1.The Ministry of Health, Labour and Welfare prohibits in principle the manufacture, import, sale, possession, and use of CBN-containing products. While procedural exceptions exist for medical and research uses, they do not permit general consumer purchase or use. Do not rely on older reviews or past articles claiming "legal" or "recommended." Source:Ministry of Health, Labour and Welfare: Designation of CBN and ProceduresThe following is a list of the most common problems with the

In addition, category-specific residual limits for Δ9-THC took effect on 2024-12-12, and any product exceeding the threshold is classified as a narcotic. These figures are product concentration standards, not intake guidelines.

Product appearance or naming alone does not determine whether an item falls under the oils/fats category. You must verify the actual product category against a lot-specific Certificate of Analysis (COA). Source:Ministry of Health, Labour and Welfare: Legal Amendments and Residual LimitsThe following is a list of the most common problems with the

4 Certificate of Analysis (COA) Checkpoints Before Purchase or Use

• Match Between Product Name and Batch / Lot Number:Whether the lot number printed on your actual container matches the lot number on the report rather than a generic sample certificate.
• Testing Laboratory and Analysis Date:Whether the name of the third-party laboratory, date of testing, and analytical method are clearly stated.
• Limit of Quantification (LOQ) and Limit of Detection (LOD) for Δ9-THC:Whether testing sensitivity is below Japan's category-specific residual limits (10ppm / 0.10ppm / 1ppm), rather than merely stating "ND (Not Detected)."
• Absence of Designated Substances (Such as CBN) and Undeclared Ingredients:Whether CBN, a designated substance since 2026-6-1, is confirmed absent.

Avoid using products without verifiable lot numbers or items from unverified sources such as social media or flea-market apps, as actual contents may differ from the label.

Why "Safe Because It Is CBD" or "Side-Effect-Free Because It Is Natural" Cannot Be Assumed

The U.S. FDA highlights risks associated with CBD including liver injury, interactions with concurrent medications, pronounced drowsiness, diarrhea, and appetite changes, while noting scientific unknowns regarding long-term use and differences across intake routes (inhalation, oral, topical). Source:FDA: Risks and Unknowns of CBD ProductsThe following is a list of the most common problems with the

Research on specific prescription CBD formulations cannot be treated as proof that commercial CBD oils, gummies, or VAPE liquids improve insomnia, relieve stress, boost immunity, or aid smoking cessation. Discontinue use immediately and consult a medical professional if you feel unwell. Anyone with preexisting conditions or taking medication should consult a physician or pharmacist rather than self-medicating.

Related:How to Read a CBD Product Certificate of Analysis (COA)／/CBD Liquid Cautions and Risks